Program
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753
Its studies are mostly in Lymphoma, B-Cell, led by Gilead Sciences.
Drug pageAutologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 3, since Mar 13, 20262 company-led studies, 2 open or runningNext primary completion: Feb 2030 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 22 open or running | phase 3since Mar 13, 2026 | Jul 26, 2021 | Feb 2030phase 2 · NCT04989803 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 26, 2021First study: phase 2 study in Relapsed and/or Refractory B-cell LymphomaFirst studyNCT04989803 · 247 enrolled · United States, Australia, Canada and more
- Mar 13, 2026Phase 3 study in RecurrencePhase 3 reachedNCT07479797 · 550 enrolled · United States, Australia, Belgium and more
Ahead
- Feb 2030Primary completion: phase 2 study in Relapsed and/or Refractory B-cell LymphomaNCT04989803
- May 2031Primary completion: phase 3 study in RecurrenceNCT07479797
TargetBeta
CD19 →read by rule
“A preparation of autologous T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19) with a ”NCIt, by rule
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| inebilizumabrule | Amgen | phase 4 | 19 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| rapcabtagene autoleucel | Novartis | phase 2 | 8 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07479797Recurrence · United States, Australia, Belgium and more | 3 | Active, not recruiting | May 2031 | 550 |
| NCT04989803Relapsed and/or Refractory B-cell Lymphoma · United States, Australia, Canada and more | 2 | Active, not recruiting | Feb 2030 | 247 |
How it is read
Names in the registry
- “KITE-753”, 2 entries
Conditions, from the studies’ own filings
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.